Hap Trading, LLC Rigel Pharmaceuticals Inc Transaction History

Hap Trading, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $45,942 - $69,497	-19,467 Reduced 16.3%	99,955 $265,000
Q3 2021 Nov 10, 2021	BUY	$3.5 - $4.5 $28,917 - $37,179	8,262 Added 7.43%	119,422 $434,000
Q2 2021 Aug 11, 2021	SELL	$3.09 - $4.54 $40,991 - $60,227	-13,266 Reduced 10.66%	111,160 $482,000
Q1 2021 May 14, 2021	BUY	$3.35 - $4.93 $62,001 - $91,244	18,508 Added 17.47%	124,426 $426,000
Q4 2020 Feb 16, 2021	BUY	$2.35 - $3.74 $13,912 - $22,140	5,920 Added 5.92%	105,918 $371,000
Q3 2020 Nov 13, 2020	BUY	$1.78 - $4.13 $177,996 - $412,991	99,998 New	99,998 $240,000
Q1 2020 May 08, 2020	SELL	$1.27 - $3.0 $125,646 - $296,802	-98,934 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$1.6 - $2.43 $158,294 - $240,409	98,934 New	98,934 $212,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.84B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.